Posted: Wednesday, May 25, 2022
The tyrosine kinase inhibitor famitinib plus the monoclonal antibody camrelizumab and nab-paclitaxel seemed to be safe and active in patients with previously untreated, advanced, immunomodulatory triple-negative breast cancer, according to Zhi-Ming Shao, MD, of the Key Laboratory of Breast Cancer in Shanghai, and colleagues. The results of the phase II FUTURE-C-Plus trial, which were published in Clinical Cancer Research, support this novel triplet regimen as a potential first-line treatment option. To validate these findings, the randomized, controlled FUTURE-SUPER trial is under way.
“This is the first study to use this approach in this subtype of breast cancer,” the investigators commented. “[It demonstrated] the best objective response rate reached in the first-line setting to treat patients with metastatic triple-negative breast cancer.”
A total of 48 patients with previously untreated, advanced, immunomodulatory triple-negative breast cancer were administered oral famitinib (20 mg on days 1–28), intravenous camrelizumab (200 mg on days 1 and 15), and intravenous nab-paclitaxel (100 mg/m2 on days 1, 8, and 15) in 4-week cycles. Follow-up data were provided for a median of 17 months.
The confirmed objective response rate was 81.3%; this included 5 and 34 patients with complete and partial responses, respectively. The median duration of progression-free survival was 13.6 months, and the median duration of response was 14.9 months. The median duration of overall survival was not reached. No treatment-related deaths were reported in this patient population. Of the 30 cases analyzed via immunohistochemistry, 13 (43.3%) were found to be PD-L1–negative; according to the investigators, PD-L1 expression was associated with favorable responses. Somatic mutations of PKD1 and KAT6A were found to be associated with responses to therapy, the study authors reported.
Disclosure: For full disclosures of the study authors, visit aacrjournals.org.